Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2021 (Event Date)
Reporting Period: Specific event date; not a periodic financial report.
Key Financial Metrics and Transaction Details
This filing reports a private placement of equity securities rather than standard operating financial metrics (revenue, profit, cash flow). The filing does not provide current revenue, profit, or margin data.
| Investor | Shares Purchased (Initial) | Shares Committed (Upon Registration) | Total Shares | Price Per Share | Total Gross Proceeds |
|---|---|---|---|---|---|
| Bespoke Growth Partners, Inc. | 33,667 | 303,000 | 336,667 | $3.00 | $1,010,001 |
| James W. Newman, Jr. (Entities) | 30,000 | 0 | 30,000 | $3.00 | $90,000 |
| Keystone Capital Partners, LLC | 33,334 | 300,000 | 333,334 | $3.00 | $1,000,002 |
| Total | 97,001 | 603,000 | 700,001 | $3.00 | $2,100,003 |
Liquidity Impact: The transaction provides immediate gross proceeds of approximately $2.1 million, subject to the issuance of additional shares upon the effectiveness of a registration statement.
Material Changes and Agreements
- Securities Purchase Agreements (SPAs): Entered into on March 11, 2021, with Bespoke, Newman entities, and Keystone.
- Registration Rights Agreements (RRAs): The Company is obligated to file a registration statement within 30 days of filing its 2020 Form 10-K and use commercially reasonable efforts to have it declared effective within 30 days (or 60 days if a full review is required).
- Related Party Transactions: Investors include Bespoke Growth Partners (controlled by the Company's Chief Strategy Officer) and entities controlled by a Board Member.
- Exemption: Securities were sold under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the execution of the capital raise and the terms of the agreements. No specific operational guidance or future revenue outlook is provided in this text.
Risks and Contingencies:
- Registration Risk: Full proceeds from Bespoke and Keystone are contingent upon the effectiveness of the Registration Statement.
- Related Party Risk: Significant portions of the investment come from individuals with management or board oversight roles.
- Marketability: Shares issued are unregistered and cannot be resold in the U.S. without an effective registration statement or exemption.
Investor Verification Checklist
- Verify the filing date of the Company's Form 10-K for the fiscal year ended December 31, 2020, to determine the deadline for the Registration Statement.
- Confirm the status of the Registration Statement (filed, effective, or under review) to assess if the contingent shares (603,000) have been issued.
- Review the Company's most recent 10-K or 10-Q for actual revenue, cash burn rate, and liquidity position, as this 8-K does not contain operating results.
- Check for any subsequent filings regarding the effectiveness of the registration statement or changes in the investment terms.